ESC 2022: FIDELITY: Finerenone in Pts With Chronic Kidney Disease | Prof Gerasimos Filippatos

Просмотров: 1, 850   |   Загружено: 2 год.
icon
Radcliffe Cardiology
icon
5
icon
Скачать
iconПодробнее о видео
Watch on Radcliffe Cardiology: *17y99ip*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2MTg1MTgzNC4yNzMuMS4xNjYxODU0NTc4LjAuMC4w

Prof Gerasimos Filippatos joins us onsite at ESC to discuss the findings of the FIDELITY study, which pooled the findings of FIDELIO-DKD and FIGARO-DKD to evaluate the impact of finerone in addition to standard care in reducing the risk of cardiovascular and renal outcomes in adult patients with chronic kidney disease (CKD). Over 13,000 patients from 48 countries were included in the study.

Recorded onsite at ESC, Barcelona, 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Похожие видео

Добавлено: 55 год.
Добавил:
  © 2019-2021
  ESC 2022: FIDELITY: Finerenone in Pts With Chronic Kidney Disease | Prof Gerasimos Filippatos - RusLar.Me